Clinipace Worldwide, a global digital contract research organization (dCRO), and Paragon Biomedical, Inc., a global, full-service contract research organization (CRO), today jointly announced a definitive merger agreement under which Clinipace Worldwide has acquired all outstanding shares of the privately-held, Irvine, CA-based company and its subsidiaries. The merger will significantly expand Clinipace Worldwide’s therapeutic expertise, site management capabilities, and clinical operations. In addition, the company extends its global footprint with the addition of offices in Irvine, California, High Wycombe, United Kingdom, and Trivandrum, India.
“Paragon is an ideal partner to achieve our common long-term goals to drive innovation in clinical research through a technology-amplified service platform. Bringing our two companies together provides the foundation for a more compelling service offering, supported by a substantial body of work spanning 20 years, a great reputation for quality, a differentiated technology-enabled clinical operations platform, a strong site management organization, and an experienced management team,” said Jeff Williams, CEO, Clinipace Worldwide. “We offer a formidable and globally integrated array of clinical development services along with strategic product development, regulatory, and GxP/CMC/QA consultancy”.
Bringing these organizations together strengthens Clinipace Worldwide’s already strong oncology franchise with additional therapeutic expertise in the areas of cardiovascular, immunology, infectious diseases, central nervous system, respiratory, dermatology, and medical device clinical research services. Clinipace Worldwide also greatly expands its global footprint with a total of 12 offices in eight countries.
Paragon clients gain access to Clinipace’s proprietary technology (TEMPO™ eClinical platform); and a comprehensive and integrated clinical operations, data management, biostatistics, and regulatory consultancy in North and South America, as well as Europe.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
The State of the Opioid Epidemic
March 26th 2024In part 1 of this video interview, Greg Sturmer, co-founder and CEO of Elysium Therapeutics discusses the current state of opioid usage including how pain treatment is often mismanaged and how the industry can adopt greater safety standards in developing pain therapies.